12 days ago
COGT
AnalystsDavid LebovitzDavid Lebovitz's Stock Forecasts
AnalystsDavid Lebovitz
Analyst Ranking
Top 28%
#1365 out of 4953 analysts
Average Return
+1.39%
Win Rate
50%58 out of 116
Risk vs Reward
Poor
Good
David Lebovitz's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Clementia Pharmaceuticals IncCMTA | +202.87% | $8.70 | $26.35 | 2018-08-12 - 2019-04-17 | Strong Buy |
Avexis IncAVXS | +129.75% | $94.81 | $217.83 | 2017-08-02 - 2018-05-15 | Strong Buy |
Avexis IncAVXS | +124.59% | $96.99 | $217.83 | 2017-11-12 - 2018-05-15 | Strong Buy |
Ascendis Pharma AASND | +107.40% | $71.19 | $147.65 | 2023-04-04 - 2024-04-04 | Strong Buy |
Bridgebio Pharma IncBBIO | +76.93% | $26.18 | $46.32 | 2024-08-01 - 2025-07-29 | Strong Buy |
David Lebovitz Analyst Color
Get additional color on David Lebovitz's coverage of popular stocks
19 days ago
BBIO
19 days ago
ASND
19 days ago
ALNY
4 months ago
ALNY
2 years ago
SDGR
3 years ago
PLRX
3 years ago
ASND
David Lebovitz's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Viking Therapeutics IncVKTX | 2 | Hold | $38.00 | +15.47% | Maintains | 7 days ago |
Cogent Biosciences IncCOGT | 4 | Strong Buy | $22.00 | +85.81% | Maintains | 12 days ago |
Bridgebio Pharma IncBBIO | 5 | Strong Buy | $67.00 | +44.65% | Maintains | 19 days ago |
Ascendis Pharma AASND | 12 | Strong Buy | $243.00 | +48.79% | Maintains | 19 days ago |
Alnylam Pharmaceuticals IncALNY | 24 | Strong Buy | $404.00 | +22.22% | Maintains | 19 days ago |
Blueprint Medicines CorpBPMC | 8 | Hold | $129.00 | -0.36% | Upgrades | 2 months ago |
Exelixis IncEXEL | 3 | Strong Buy | $56.00 | +51.60% | Maintains | 3 months ago |
Intellia Therapeutics IncNTLA | 8 | Hold | $10.00 | -20.00% | Maintains | 3 months ago |
Cytokinetics IncCYTK | 2 | Strong Buy | $80.00 | +122.84% | Maintains | 3 months ago |
Biomarin Pharmaceutical IncBMRN | 7 | Hold | $78.00 | +33.95% | Maintains | 3 months ago |
Pliant Therapeutics IncPLRX | 6 | Hold | $1.50 | +2.74% | Maintains | 5 months ago |
Madrigal Pharmaceuticals IncMDGL | 5 | Strong Buy | $469.00 | +59.31% | Maintains | 5 months ago |
Ionis Pharmaceuticals IncIONS | 10 | Strong Buy | $64.00 | +54.29% | Maintains | 5 months ago |
Ptc Therapeutics IncPTCT | 9 | Strong Sell | $45.00 | -8.70% | Maintains | 6 months ago |
Incyte CorpINCY | 5 | Strong Buy | $88.00 | +13.73% | Maintains | 6 months ago |
Crinetics Pharmaceuticals IncCRNX | 2 | Strong Buy | $74.00 | +152.82% | Maintains | 9 months ago |
Mirum Pharmaceuticals IncMIRM | 5 | Strong Buy | $68.00 | +32.89% | Maintains | 9 months ago |
Celldex Therapeutics IncCLDX | 1 | Strong Buy | $70.00 | +218.91% | Initiates Coverage On | 10 months ago |
Schrodinger IncSDGR | 7 | Strong Buy | $37.00 | N/A | Maintains | a year ago |
Immuneering CorpIMRX | 2 | Hold | $12.00 | N/A | Maintains | 3 years ago |
Arcutis Biotherapeutics IncARQT | 5 | Strong Buy | $36.00 | N/A | Maintains | 3 years ago |
Syndax Pharmaceuticals IncSNDX | 1 | Hold | $21.00 | N/A | Maintains | 4 years ago |
Karyopharm Therapeutics IncKPTI | 3 | Strong Buy | $405.00 | N/A | Maintains | 4 years ago |
Ironwood Pharmaceuticals IncIRWD | 5 | Hold | $14.00 | N/A | Maintains | 4 years ago |
Tectonic Therapeutic IncTECX | 7 | Strong Buy | $300.00 | N/A | Maintains | 4 years ago |
Epizyme IncEPZM | 2 | Strong Sell | $5.00 | N/A | Downgrades | 4 years ago |
Rhythm Pharmaceuticals IncRYTM | 2 | Strong Buy | $57.00 | N/A | Maintains | 4 years ago |
Macrogenics IncMGNX | 1 | Strong Sell | $15.00 | N/A | Maintains | 4 years ago |
Gw Pharmaceuticals PLCGWPH | 1 | Hold | $220.00 | N/A | Downgrades | 4 years ago |
Nabriva Therapeutics PLCNBRVF | 2 | Hold | $500.00 | N/A | Maintains | 5 years ago |
Zealand Pharma AZEAL | 1 | Strong Buy | $37.00 | N/A | Maintains | 5 years ago |
Clementia Pharmaceuticals IncCMTA | 2 | Strong Buy | $26.00 | N/A | Maintains | 7 years ago |
Avexis IncAVXS | 3 | Strong Buy | $129.00 | N/A | Maintains | 7 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.